<?xml version='1.0' encoding='utf-8'?>
<document id="29311077"><sentence text="Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis."><entity charOffset="0-12" id="DDI-PubMed.29311077.s1.e0" text="Posaconazole" /></sentence><sentence text="Appropriate exposure to posaconazole (PSZ) has been limited until the recent approval of the delayed-release oral tablet formulation"><entity charOffset="24-36" id="DDI-PubMed.29311077.s2.e0" text="posaconazole" /><entity charOffset="38-41" id="DDI-PubMed.29311077.s2.e1" text="PSZ" /><pair ddi="false" e1="DDI-PubMed.29311077.s2.e0" e2="DDI-PubMed.29311077.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29311077.s2.e0" e2="DDI-PubMed.29311077.s2.e1" /></sentence><sentence text=" Our goal was to determine the exposure obtained by using the standard dose of 300 mg once a day in lung transplant (LT) patients, including patients with cystic fibrosis (CF)" /><sentence text=" PSZ trough concentrations (C0) were determined using a liquid chromatography-tandem mass spectrometry assay"><entity charOffset="1-3" id="DDI-PubMed.29311077.s4.e0" text="PSZ" /></sentence><sentence text=" Indicative thresholds of interest were &lt;0" /><sentence text="7 mg/liter for prophylaxis and 1 to 3 mg/liter for cure" /><sentence text=" The tacrolimus (TRL) and everolimus (ERL) C0 measured during PSZ exposure were also collected"><entity charOffset="5-15" id="DDI-PubMed.29311077.s7.e0" text="tacrolimus" /><entity charOffset="17-20" id="DDI-PubMed.29311077.s7.e1" text="TRL" /><entity charOffset="26-36" id="DDI-PubMed.29311077.s7.e2" text="everolimus" /><entity charOffset="38-41" id="DDI-PubMed.29311077.s7.e3" text="ERL" /><entity charOffset="62-64" id="DDI-PubMed.29311077.s7.e4" text="PSZ" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e0" e2="DDI-PubMed.29311077.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e0" e2="DDI-PubMed.29311077.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e0" e2="DDI-PubMed.29311077.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e0" e2="DDI-PubMed.29311077.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e0" e2="DDI-PubMed.29311077.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e1" e2="DDI-PubMed.29311077.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e1" e2="DDI-PubMed.29311077.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e1" e2="DDI-PubMed.29311077.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e1" e2="DDI-PubMed.29311077.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e2" e2="DDI-PubMed.29311077.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e2" e2="DDI-PubMed.29311077.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e2" e2="DDI-PubMed.29311077.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e3" e2="DDI-PubMed.29311077.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29311077.s7.e3" e2="DDI-PubMed.29311077.s7.e4" /></sentence><sentence text=" The interaction with proton-pump inhibitors (PPI) was evaluated" /><sentence text=" We recorded the results for 21 CF patients with LT (CFLT patients), 11 non-CF patients with LT (NCFLT patients), and 27 nontransplant (NT) patients in pneumology departments" /><sentence text=" The weights of the NCFLT, CFLT, and NT patients were 59" /><sentence text="2 ± 8" /><sentence text="4, 48" /><sentence text="8 ± 8" /><sentence text="4, and 63" /><sentence text="7 ± 16" /><sentence text="6 kg, respectively (P = 0" /><sentence text="001* [asterisk means that statistical test is significant]), and the PSZ C0 exposures for these patients were 1"><entity charOffset="69-71" id="DDI-PubMed.29311077.s17.e0" text="PSZ" /></sentence><sentence text="9 ± 1" /><sentence text="5, 1" /><sentence text="1 ± 0" /><sentence text="8, and 2" /><sentence text="4 ± 1" /><sentence text="8 mg/liter, respectively (P &lt; 0" /><sentence text="00001*)" /><sentence text=" More than 60% of the concentrations were in the therapeutic range" /><sentence text=" In CFLT patients, the administration of one 300-mg PSZ tablet quickly achieved an exposure similar to that achieved with the PSZ oral suspension formulation (OSF) administered 3 or 4 times a day for several months"><entity charOffset="52-54" id="DDI-PubMed.29311077.s26.e0" text="PSZ" /><entity charOffset="126-128" id="DDI-PubMed.29311077.s26.e1" text="PSZ" /><pair ddi="false" e1="DDI-PubMed.29311077.s26.e0" e2="DDI-PubMed.29311077.s26.e0" /><pair ddi="false" e1="DDI-PubMed.29311077.s26.e0" e2="DDI-PubMed.29311077.s26.e1" /></sentence><sentence text=" The TRL C0/dose ratio (C0/D) was 7"><entity charOffset="5-7" id="DDI-PubMed.29311077.s27.e0" text="TRL" /></sentence><sentence text="4 ± 4" /><sentence text="4 mg/liter with PSZ tablets, whereas it was 4"><entity charOffset="16-18" id="DDI-PubMed.29311077.s29.e0" text="PSZ" /></sentence><sentence text="6 ± 0" /><sentence text="8 mg/liter with the PSZ oral solution (P = 0"><entity charOffset="20-22" id="DDI-PubMed.29311077.s31.e0" text="PSZ" /></sentence><sentence text="034*)" /><sentence text=" The ERL C0/D was similar with both formulations"><entity charOffset="5-7" id="DDI-PubMed.29311077.s33.e0" text="ERL" /></sentence><sentence text=" PPI had no impact on the PSZ concentration (1"><entity charOffset="26-28" id="DDI-PubMed.29311077.s34.e0" text="PSZ" /></sentence><sentence text="49 ± 1" /><sentence text="07 mg/liter without PPI versus 1" /><sentence text="33 ± 1" /><sentence text="17 mg/liter with PPI; P = 0" /><sentence text="4134*)" /><sentence text=" Despite the high levels of exposure, PSZ remained well tolerated (one case of diarrhea and one case of fatigue were reported)"><entity charOffset="38-40" id="DDI-PubMed.29311077.s40.e0" text="PSZ" /></sentence><sentence text=" PSZ tablet administration allows satisfactory exposure, even in CFLT patients, with a dosage lower than that of the PSZ OSF"><entity charOffset="1-3" id="DDI-PubMed.29311077.s41.e0" text="PSZ" /><entity charOffset="117-119" id="DDI-PubMed.29311077.s41.e1" text="PSZ" /><pair ddi="false" e1="DDI-PubMed.29311077.s41.e0" e2="DDI-PubMed.29311077.s41.e0" /><pair ddi="false" e1="DDI-PubMed.29311077.s41.e0" e2="DDI-PubMed.29311077.s41.e1" /></sentence><sentence text=" This once-a-day formulation was not impacted by PPI, which are extensively used in CF patients" /><sentence text="" /></document>